Light Sciences Oncology, Inc. (LSO) today announced the election of Dennis Langer, M.D., J.D. to the Company’s Board of Directors and his appointment as the Chairman of the Executive Committee. LSO expects data to be available during the second half of this year from two phase 3 trials of light-activated talaporfin sodium in patients with primary and secondary liver tumors.
